Humacyte V007 Phase 3 ATEV data published in Lancet Digital Health
Humacyte has announced publication of one-year results from its V007 Phase 3 clinical trial in The Lancet Digital Health, providing peer-reviewed validation for data that had previously been presented only at medical conferences. The trial evaluated the company's acellular tissue engineered vessel (ATEV), marketed as Symvess, against the standard autogenous arteriovenous fistula (AVF) for haemodialysis vascular access in patients with end-stage kidney disease.
The published results show that ATEV was superior to AVF after one year of follow-up in two specific patient populations: all female patients, and male patients with both obesity and diabetes. These groups carry disproportionately high rates of AVF failure, making reliable vascular access a persistent clinical problem. Mohamad Hussain, lead author of the publication and a vascular surgeon at Mass General Brigham with an appointment at Harvard Medical School, said the findings "highlight the potential of ATEV as an alternative for patients who may be less likely to benefit from AV fistulas."
Clinical programme and regulatory path
The V007 publication sits alongside a broader body of evidence Humacyte has assembled across two Phase 3 trials. Two-year follow-up data from V007, presented at the American Society of Nephrology's Kidney Week in November 2025, showed that the superiority advantage over AVF was maintained over the longer observation window. Separately, top-line interim results from the V012 trial, reported in June 2026 at the Society of Vascular Surgery's annual meeting in Boston, demonstrated that ATEV met the primary superiority endpoint in a study focused exclusively on female patients with end-stage renal disease.
On the strength of the V012 readout, Humacyte said it intends to submit a supplemental Biologics License Application to the FDA in the second half of 2026, seeking to expand the Symvess label to cover arteriovenous access for haemodialysis. Symvess already holds FDA approval in the extremity vascular trauma indication, granted in December 2024. The haemodialysis application remains investigational and does not yet carry regulatory clearance.
Laura Niklason, founder and chief executive of Humacyte, described the combined V007 and V012 evidence as a "compelling case" for the patient populations most likely to benefit, and framed the Lancet publication as a significant commercial and scientific milestone for the company.
Market context and competitive landscape
Vascular access failure is a leading source of hospitalisation and morbidity in the haemodialysis population, and the inadequacy of AVFs in certain patient groups has been a recognised clinical gap for years. The current standard of care offers two main options: the autogenous fistula, which is preferred in guidelines but fails at high rates in women and patients with comorbidities, and synthetic grafts made from expanded polytetrafluoroethylene (ePTFE), which carry their own infection and thrombosis risks.
Humacyte's ATEV occupies a distinct niche: an acellular, bioengineered scaffold designed to remodel into functional vascular tissue and resist infection. The product's RMAT designation and FDA Fast Track status reflect the agency's recognition of its potential in an area of unmet need. Should the sBLA succeed, Humacyte would gain a commercially approved product in a large and recurrent patient population, which would materially change the company's revenue outlook relative to its current trauma-focused commercial footprint.
Beyond haemodialysis, Humacyte is advancing ATEV in peripheral artery disease and early-stage programmes in coronary artery bypass, paediatric cardiac surgery, and type 1 diabetes, suggesting the platform strategy extends well beyond a single vascular indication. Investors will watch the sBLA submission timing and any FDA feedback on the completeness of the dossier as the next material catalyst.